NASDAQ:OBSV - ObsEva Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $14.33
  • Forecasted Upside: 539.88 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$2.24
+0.30 (1.20%)

This chart shows the closing price for OBSV by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ObsEva Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OBSV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OBSV

Analyst Price Target is $14.33
▲ +539.88% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for ObsEva in the last 3 months. The average price target is $14.33, with a high forecast of $21.00 and a low forecast of $5.00. The average price target represents a 539.88% upside from the last price of $2.24.

This chart shows the closing price for OBSV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in ObsEva. This rating has held steady since June 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/5/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 1 sell ratings
9/3/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 1 sell ratings
12/2/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
3/2/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
5/31/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
8/29/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
10/28/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/17/2021WedbushReiterated RatingBuy$21.00High
9/15/2021HC WainwrightReiterated RatingBuy$17.00Medium
8/9/2021HC WainwrightReiterated RatingBuy$17.00Low
7/28/2021WedbushReiterated RatingBuy$21.00Low
7/2/2021WedbushReiterated RatingBuy$24.00N/A
1/12/2021WedbushReiterated RatingBuy$28.00Low
1/12/2021SVB LeerinkBoost Price TargetOutperform$4.00 ➝ $5.00Low
1/4/2021HC WainwrightLower Price TargetBuy$23.00 ➝ $17.00N/A
11/9/2020JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightMedium
10/5/2020HC WainwrightLower Price TargetBuy$36.00 ➝ $23.00High
8/14/2020WedbushReiterated RatingBuy$30.00High
7/7/2020SVB LeerinkLower Price TargetOutperform$7.00 ➝ $5.00High
7/7/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$18.00 ➝ $5.00High
7/6/2020BMO Capital MarketsDowngradeOutperform ➝ Market Perform$5.00 ➝ $4.00High
7/1/2020HC WainwrightReiterated RatingBuy$36.00Low
7/1/2020WedbushReiterated RatingBuy$30.00Low
6/5/2020HC WainwrightReiterated RatingBuy$36.00High
5/5/2020WedbushReiterated RatingBuy$30.00High
3/23/2020WedbushReiterated RatingBuy$40.00 ➝ $34.00Medium
3/23/2020HC WainwrightLower Price TargetBuy$40.00 ➝ $36.00Low
3/5/2020WedbushBoost Price TargetOutperform$36.00 ➝ $40.00High
1/21/2020WedbushReiterated RatingBuy$36.00High
1/21/2020HC WainwrightReiterated RatingBuy$40.00High
12/19/2019HC WainwrightReiterated RatingBuy ➝ Buy$36.00 ➝ $40.00High
12/10/2019Royal Bank of CanadaBoost Price TargetOutperform$18.00 ➝ $19.00High
12/2/2019HC WainwrightReiterated RatingBuy$44.00 ➝ $36.00Low
11/8/2019Credit Suisse GroupDowngradeOutperform ➝ Neutral$16.00 ➝ $4.00High
10/31/2019WedbushReiterated RatingBuy$38.00Medium
10/11/2019WedbushSet Price TargetBuy$38.00Low
9/4/2019HC WainwrightReiterated RatingBuy$44.00Low
8/11/2019Royal Bank of CanadaReiterated RatingBuyLow
7/29/2019Credit Suisse GroupLower Price TargetOutperform$24.00 ➝ $16.00Medium
7/18/2019WedbushReiterated RatingOutperform$38.00High
7/8/2019WedbushSet Price TargetBuy$38.00Low
6/19/2019WedbushReiterated RatingBuy$38.00Medium
6/5/2019HC WainwrightSet Price TargetBuy$44.00Medium
5/28/2019HC WainwrightReiterated RatingBuy$44.00Low
5/10/2019WedbushSet Price TargetBuy$38.00Medium
5/6/2019HC WainwrightReiterated RatingBuyLow
4/29/2019HC WainwrightReiterated RatingBuyLow
3/7/2019HC WainwrightSet Price TargetBuy$44.00Low
1/25/2019WedbushSet Price TargetBuy$34.00High
1/23/2019HC WainwrightSet Price TargetBuy$44.00Low
1/15/2019WedbushSet Price TargetBuy$34.00High
1/4/2019HC WainwrightSet Price TargetBuy$44.00Low
12/11/2018WedbushReiterated RatingBuy$34.00Low
12/10/2018HC WainwrightReiterated RatingBuy$44.00Low
10/15/2018HC WainwrightSet Price TargetBuy$44.00Low
10/3/2018WedbushSet Price TargetBuy$34.00High
9/13/2018JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$29.00Low
8/29/2018HC WainwrightSet Price TargetBuy$44.00High
8/15/2018SVB LeerinkInitiated CoverageOutperform$25.00Low
8/8/2018HC WainwrightSet Price TargetBuy$44.00High
8/6/2018WedbushInitiated CoverageOutperform$34.00High
7/25/2018HC WainwrightSet Price TargetBuy$30.00Low
7/19/2018Credit Suisse GroupInitiated CoverageOutperform$24.00Low
7/16/2018HC WainwrightSet Price TargetBuy$30.00High
6/18/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$23.00 ➝ $31.00High
6/12/2018BMO Capital MarketsInitiated CoverageOutperform$23.00High
6/11/2018HC WainwrightSet Price TargetBuy$28.00Low
5/29/2018HC WainwrightReiterated RatingBuy$28.00Medium
3/9/2018HC WainwrightReiterated RatingBuy$27.00Low
2/27/2018BMO Capital MarketsReiterated RatingBuy$24.00High
2/27/2018SVB LeerinkBoost Price TargetOutperform ➝ Outperform$17.00 ➝ $18.00High
2/27/2018Credit Suisse GroupReiterated RatingOutperform ➝ Buy$16.00 ➝ $18.00Low
2/5/2018HC WainwrightReiterated RatingBuy$25.00Low
1/4/2018HC WainwrightSet Price TargetBuy$25.00Low
12/14/2017HC WainwrightSet Price TargetBuy$25.00Low
12/4/2017BMO Capital MarketsInitiated CoverageOutperform$20.00Low
11/29/2017HC WainwrightSet Price TargetBuy$25.00Low
11/8/2017HC WainwrightReiterated RatingBuy$25.00N/A
11/2/2017Royal Bank of CanadaReiterated RatingBuy$22.00N/A
10/30/2017HC WainwrightSet Price TargetBuy$25.00N/A
10/11/2017HC WainwrightReiterated RatingBuy ➝ Buy$27.00 ➝ $25.00N/A
10/9/2017Credit Suisse GroupInitiated CoverageOutperform$27.00 ➝ $16.00N/A
10/4/2017HC WainwrightReiterated RatingBuy$27.00High
9/14/2017Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$22.00Low
9/8/2017HC WainwrightReiterated RatingBuy$27.00Low
8/16/2017SVB LeerinkReiterated RatingOutperform ➝ Outperform$18.00High
8/16/2017HC WainwrightSet Price TargetBuy$27.00Low
6/29/2017HC WainwrightInitiated CoverageBuy ➝ Buy$27.00High
4/18/2017Credit Suisse GroupReiterated RatingOutperform$27.00Low
2/21/2017SVB LeerinkInitiated CoverageOutperform$21.00N/A
2/21/2017Credit Suisse GroupInitiated CoverageOutperform ➝ Outperform$27.00N/A
2/21/2017Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$21.00N/A
(Data available from 11/27/2016 forward)

News Sentiment Rating

0.39 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/1/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 1 very positive mentions
  • 7 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
7/30/2021
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/29/2021
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/28/2021
  • 0 very positive mentions
  • 9 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
10/28/2021
  • 3 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/27/2021

Current Sentiment

  • 3 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
ObsEva logo
ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for woman's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.
Read More

Today's Range

Now: $2.24
Low: $2.17
High: $2.25

50 Day Range

MA: $2.75
Low: $2.19
High: $3.34

52 Week Range

Now: $2.24
Low: $1.93
High: $5.55

Volume

386,807 shs

Average Volume

2,567,646 shs

Market Capitalization

$174.66 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.64

Frequently Asked Questions

What sell-side analysts currently cover shares of ObsEva?

The following Wall Street sell-side analysts have issued reports on ObsEva in the last year: HC Wainwright, SVB Leerink LLC, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for OBSV.

What is the current price target for ObsEva?

3 Wall Street analysts have set twelve-month price targets for ObsEva in the last year. Their average twelve-month price target is $14.33, suggesting a possible upside of 539.9%. Wedbush has the highest price target set, predicting OBSV will reach $21.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $5.00 for ObsEva in the next year.
View the latest price targets for OBSV.

What is the current consensus analyst rating for ObsEva?

ObsEva currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OBSV will outperform the market and that investors should add to their positions of ObsEva.
View the latest ratings for OBSV.

How do I contact ObsEva's investor relations team?

ObsEva's physical mailing address is Chemin des Aulx 12 Plan-les-Ouates, Geneva V8, 1228. The company's listed phone number is (122) 552-3840 and its investor relations email address is [email protected] The official website for ObsEva is www.obseva.com.